Zobrazeno 51 - 60
of 141
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
Li, Wenlong, Sparidans, Rolf W., Wang, Yaogeng, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H., Afd Pharmacoepi & Clinical Pharmacology, Afd Chemical Biology and Drug Discovery, Pharmacoepidemiology and Clinical Pharmacology, Chemical Biology and Drug Discovery
Publikováno v:
Pharmacological Research, 137, 47. Academic Press Inc.
Brigatinib is an FDA-approved oral anaplastic lymphoma kinase (ALK) inhibitor for treatment of metastatic non-small cell lung cancer (NSCLC). Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60fd875538f0101a346c51b59df46cc0
https://dspace.library.uu.nl/handle/1874/374357
https://dspace.library.uu.nl/handle/1874/374357
Autor:
Li, Wenlong, Sparidans, Rolf W, Wang, Yaogeng, Lebre, Maria C, Wagenaar, Els, Beijnen, Jos H, Schinkel, Alfred H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
International Journal of Cancer, 143(8), 2029. Wiley-Liss Inc.
Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. With therapy-resistant brain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43adde3558244fd803479b5c45f2004
https://dspace.library.uu.nl/handle/1874/371773
https://dspace.library.uu.nl/handle/1874/371773
Autor:
Hendrikx, Jeroen J M A, Stuurman, Frederik E, Song, Ji-Ying, de Weger, Vincent A, Lagas, Jurjen S, Rosing, Hilde, Beijnen, Jos H, Schinkel, Alfred H, Schellens, Jan H M, Marchetti, Serena, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives
Pharmacology research & perspectives, 8(4). Wiley-Blackwell Publishing Ltd
Pharmacology Research & Perspectives
Pharmacology research & perspectives, 8(4). Wiley-Blackwell Publishing Ltd
Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity. This study combined pre
Autor:
de Jong, Corine, Deneer, Vera H.M., Kelder, Johannes C., Ruven, Henk, Egberts, Toine C.G., Herder, Gerarda J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Thoracic Cancer, 11(7), 1790. Blackwell Publishing Asia Pty Ltd
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 7, Pp 1790-1800 (2020)
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 7, Pp 1790-1800 (2020)
Background In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision-making. The objective of this study was to investigate carcinoembryonic antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4509620a259b07436012699b43bbe48a
https://dspace.library.uu.nl/handle/1874/408616
https://dspace.library.uu.nl/handle/1874/408616
Autor:
Rood, Johannes J M, Jamalpoor, Amer, van Hoppe, Stephanie, van Haren, Matthijs J, Wasmann, Roeland E, Janssen, Manoe J, Schinkel, Alfred H, Masereeuw, Rosalinde, Beijnen, Jos H, Sparidans, Rolf W, Afd Pharmacoepi & Clinical Pharmacology, Afd Pharmacology, Afd Chemical Biology and Drug Discovery, Pharmacoepidemiology and Clinical Pharmacology, Pharmacology, Chemical Biology and Drug Discovery
Publikováno v:
Investigational New Drugs, 39(1), 1. Kluwer Academic Publishers
Investigational New Drugs
Investigational New Drugs
Summary Ibrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally
Autor:
Vranken, Marjolein J M, Mantel-Teeuwisse, Aukje K, Schutjens, Marie-Hélène D B, Scholten, Willem K, Jünger, Saskia, Medic, Dr Rer, Leufkens, Hubert G M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Palliative Medicine, 21(7), 963. Mary Ann Liebert inc
BACKGROUND: In 2011-2013, >95% of the global opioid analgesics consumption occurred in three regions, accounting for 15% of the world population. Despite abundant literature on barriers to access, little is known on the correlation between actual acc
Autor:
Pluim, Dick, Ros, Willeke, Miedema, Iris H C, Beijnen, Jos H, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Cytometry. Part A : the journal of the International Society for Analytical Cytology, 95(10), 1053. Wiley-Liss Inc.
We report the development and validation of a 12 parameter immunofluorescence flow cytometry method for the sensitive determination of cell concentrations, their expression of PD-1, and PD-1 receptor occupancy. Cell subsets include CD4+ and CD8+ -T-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::395c9a523f14c38fbf21e2533f9c3375
https://dspace.library.uu.nl/handle/1874/407874
https://dspace.library.uu.nl/handle/1874/407874
Autor:
Henricks, Linda M, Opdam, Frans L, Beijnen, J H, Cats, A., Schellens, J H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Annals of Oncology, 28(12), 2915. Oxford University Press
The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including breast, colorectal, head and neck and gastric cancer. In the current drug labels of 5-FU and ca
Autor:
Wong, Dennis R, Coenen, Marieke J H, Vermeulen, Sita H, Derijks, Luc J J, van Marrewijk, Corine J, Klungel, Olaf H, Scheffer, Hans, Franke, Barbara, Guchelaar, Henk-Jan, de Jong, Dirk J, Engels, Leopold G J B, Verbeek, André L M, Hooymans, Piet M, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Journal of Crohn's and Colitis, 11, 2, pp. 175-184
Journal of Crohn's & Colitis, 11(2), 175. Oxford University Press
Journal of Crohn's and Colitis, 11, 175-184
Journal of Crohn's and Colitis, 11(2), 175-184
Journal of Crohn's & Colitis, 11(2), 175. Oxford University Press
Journal of Crohn's and Colitis, 11, 175-184
Journal of Crohn's and Colitis, 11(2), 175-184
Background and aims: Only a quarter of thiopurine-induced myelotoxicity in inflammatory bowel disease [IBD] patients is related to thiopurine S-methyltransferase deficiency. We determined the predictive value of 6-thioguanine nucleotide [6-TGN] and 6
Autor:
Maliepaard, Marc, Toiviainen, Timi, De Bruin, Marie L., Meulendijks, Didier, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 108, 338-349
Clinical Pharmacology and Therapeutics, 108, 2, pp. 338-349
Clinical Pharmacology and Therapeutics, 108(2), 338. Nature Publishing Group
Maliepaard, M, Toiviainen, T, De Bruin, M L & Meulendijks, D 2020, ' Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency between 2014 and 2017 ', Clinical Pharmacology and Therapeutics, vol. 108, no. 2, pp. 338-349 . https://doi.org/10.1002/cpt.1834
Clinical Pharmacology and Therapeutics, 108, 338-349
Clinical Pharmacology and Therapeutics, 108, 2, pp. 338-349
Clinical Pharmacology and Therapeutics, 108(2), 338. Nature Publishing Group
Maliepaard, M, Toiviainen, T, De Bruin, M L & Meulendijks, D 2020, ' Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency between 2014 and 2017 ', Clinical Pharmacology and Therapeutics, vol. 108, no. 2, pp. 338-349 . https://doi.org/10.1002/cpt.1834
Contains fulltext : 225993.pdf (Publisher’s version ) (Open Access) This study aimed to determine to which extent data on potential pharmacogenetic-pharmacokinetic (PG-PK) interactions are provided to, and assessed by, the European Medicines Agency